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Introduction 
Phosphorus is an essential mineral in the human body (2). The majority of the body’s 
phosphorus, approximately 85%, is stored in the bones, while the rest is mainly stored in cells, 
where it’s used for energy production and DNA synthesis (3). Under normal conditions, the body 
mainly excretes phosphorus in the urine. In individuals with chronic kidney disease (CKD), 
where kidney function is diminished and eventually absent, it becomes harder for the body to 
excrete phosphorus. For individuals on dialysis, phosphorus intake through the diet is generally 
more than phosphorus removal through the dialysate, increasing the risk of hyperphosphatemia 
(4). In general, only approximately 800 mg of phosphorus is removed per treatment, regardless 
of pre-dialysis serum levels (19). Hyperphosphatemia is an independent risk factor for 
cardiovascular disease (CVD) and mortality (1). Therefore, serum phosphorus control is 
extremely important in the dialysis population. Phosphorus also plays an important part on bone 
mineral metabolism with calcium and PTH. 
 Phosphorus binders are often prescribed to dialysis patients to help control serum 
phosphorus levels. Binders work to decrease phosphorus absorption by binding the phosphorus 
in the gut, allowing it to be excreted in the stool (5). However, not all binders are created equally, 
and there has been growing concern that calcium-based binders are increasing the risk for 
cardiovascular disease by disrupting bone mineral metabolism. In this paper, I discuss what I 
have learned regarding the influences on serum phosphorus, the different types of phosphorus 
binders, why binders are crucial in phosphorus control, and the risks and benefits associated with 
binders. Additionally, I will take a deeper dive into the binder Velphoro and close with how to 
practically integrate this knowledge and apply it to the real world. 
 
Factors That Influence Serum Phosphorus Levels 
In patients on dialysis, serum phosphorus levels are regulated through multiple channels. 
Two main ways serum phosphorus is regulated are through dietary modifications and adherence 
to phosphorus binder medications (25). Factors that have a lesser but still notable roll in 
phosphorus regulation are adherence to dialysis prescription, vitamin D intake, and 
calcimimetics (24,25,28,29). The reason dialysis prescription adherence doesn’t play as large a 
roll as diet and medication adherence is that hemodialysis only removes between 800-1000 mg 
of phosphorus per session (2400-3000 mg per week, compared to an average recommended 
intake of 5600-7000 mg per week) (25).  
There are multiple reasons why someone might continue to have high serum phosphorus 
despite being on a phosphorus binder and trying to comply with the renal diet. First, dialysis, 
while it only removes a fraction of phosphorus intake, is important in maintaining phosphorus. If 
a patient is non-compliant with the dialysis prescription by missing or having shortened 
treatments, phosphorus that would have been removed instead remains in the body (25). Second, 
despite an individual’s good intentions in limiting phosphorus intake, protein intake is extremely 
important in dialysis, and phosphorus and protein are often found in the same foods (25). This 
can make it difficult to maintain protein status while limiting phosphorus intake. Additionally, 
when an individual limits phosphorus intake, the body has a natural mechanism that then 
increases the absorption of whatever phosphorus is present in the GI tract to prevent 
hypophosphatemia (25). Third, inorganic phosphorus additives are becoming more prevalent in 
fast and processed foods and are close to 100% bioavailable compared to organic phosphorus 
naturally found in foods (25). These foods are readily available and often the easiest choice for 
individuals with less time, money, or access to invest in cooking at home. Lastly, there are 
patients who are prescribed calcitriol for low serum calcium levels, which in addition to 
increasing calcium absorption also increase phosphorus absorption (2).  
Of course, despite being prescribed a phosphorus binder and educated on the renal diet, 
there is also the issue of non-compliance. There are many reasons a patient might be non-
compliant. The pill burden of the phosphorous binders might be too much for the patient, the size 
of the phosphorus binder pill might be too large to swallow, the current phosphorus binder might 
have unwanted GI issues, the patient might find the renal diet to be too restrictive, an 
individual’s cultural foods are high in phosphorus and/or potassium and therefore the patient is 
struggling with limiting these foods, and the patient simply might not be ready to make changes. 
These are just some of the reasons given by patients at Fresenius Kidney Care Rocky Mountain 
in Denver, Colorado.   
 
Types and Efficacy of Binders 
Generally speaking, there are two main types of phosphorus binders: 1) calcium-based 
phosphorus binders and 2) non-calcium-based phosphorus binders. Calcium-based binders 
include calcium acetate (Eliphos, Phoslo) and calcium carbonate (Tums) (7). Non-calcium-based 
binders include sevelamer carbonate (Renvela), sevelamer hydrochloride (Renagel), lanthanum 
carbonate (Fosrenol), and magnesium salts (16), as well as the more recently FDA approved 
Iron-based binders like sucroferric oxyhydroxide (Velphoro) and ferric citrate (Auryxia) (17) 
(18). Some binders have contraindications, so each person’s needs should be taken into account 
when prescribing. According to the National Kidney Foundation’s Kidney Disease Outcomes 
Quality Initiative (KDOQI), a globally accepted group that publishes clinical guidelines in 
nephrology, all binders have been shown to effectively lower serum phosphorus levels (22,23), 
but studies have shown some binders are more effective than others at lowering serum 
phosphorus, after titrated to the appropriate dose (27). For example, one pill of calcium acetate 
(667 mg) binds less than approximately 106 mg phosphorus, whereas 1 tablet of Velphoro binds 
130 mg phosphorus (32,33). The efficacy of Velphoro compared to other phosphorus binders in 
controlling laboratory values will be discussed more in detail later in this paper. In addition to 
the variability in efficacy, there is growing that the use of calcium- versus non-calcium-based 
binders in managing serum phosphorus levels has the potential to increase risk for cardiovascular 
disease, vascular calcification, and all-cause mortality. 
 
Calcium Based Binders and Cardiovascular Disease 
There has been growing concern that calcium-based binders might be linked to an 
increased risk for cardiovascular disease due to vascular calcification. Cardiovascular mortality 
accounts for 50% of deaths in patients on dialysis (27). Calcium has multiple functions in the 
body, including maintaining bone health, muscle contraction, and blood clotting. However, like 
many other vitamins and minerals, there is a limit set on the amount of calcium recommended 
for daily consumption (11). The main storage site of calcium in the body is bone, but in CKD, 
when the kidneys’ function is diminished or non-existent, excess dietary and supplemental 
calcium that has been absorbed into the body has lost its main method of excretion, allowing 
calcium to then build up in the body and deposit in soft tissues, causing calcification. One of the 
areas excess calcium can deposit is in the vasculature of the heart, which is associated with 
increased risk for cardiovascular disease.  
Most individuals prescribed a calcium-based binder take anywhere from 1-4 pills per 
meal, which equates to 169 mg – 676 mg of additional calcium per meal (for calcium acetate), or 
507 mg – 2,028 mg of additional calcium per day on top of dietary intake (7,19).  The absorption 
rate for dietary calcium is 20-30% when doses are kept below 500 mg calcium at any given time, 
however, absorption rates for calcium supplements differ and are not well studied (20, 21). To 
put this in perspective, the Recommended Dietary Allowance (RDA) for women aged 19 to 50 
years old and men aged 19 to 70 years old is 1,000 mg per day (8,20). This increases to 1,200 mg 
per day in women 50+ years old and men 70+ years old (8,11,20). The Upper Level (UL) for 
both women and men aged 19-50 years old is 2500 mg per day and for those aged 51+ years old 
is 2,000 mg per day (11). Given the quantity of calcium-based binders required to successfully 
manage hyperphosphatemia and under the assumption that most of the elemental calcium in the 
calcium-based binders is absorbed, some individuals on dialysis are exceeding the UL for 
calcium in phosphorus binders alone. 
The literature also suggests that there is a paradox between dietary calcium, supplemental 
calcium, and CVD risk. A 2016 study published in The Journal of the American Heart 
Association states that high supplemental calcium intake with low dietary calcium intake might 
be at increased risk of incident coronary artery calcium (CAC) (9). CAC is an established value 
for assessing CVD risk (53). Conversely, those with low supplemental calcium intake but high 
dietary calcium intake had decreased risk of incident CAC, showing a protective effect of dietary 
calcium (9). However, individuals with impaired kidney function were excluded from this 
study(9). In another systematic review of eight studies looking at circulating calcium 
concentrations, vascular disease, and mortality, there was a hazard ratio of death of 1.13 (95% CI 
1.09,1.18) per standard deviation of serum calcium, however, this meta-analysis also excluded 
any studies that involved the CKD population and only looked at normocalcaemic populations 
(10). Of the 8 studies analyzed, only 1 of them was an RCT looking specifically at calcium 
supplements and adverse cardiovascular events (52). When looking at phosphorus binders 
specifically, a 2013 meta-analysis found that non-calcium-based binders had a statistically 
significant decreased risk (RR 0.78, 95% CI 0.61,0.98) of all-cause mortality compared to 
calcium-based binders in the CKD population (6). This was an update of their 2009 meta-
analysis where no statistically significant change in all-cause mortality risk was found between 
calcium-based binders and non-calcium-based binders (26). While these studies seem to support 
the claim that high calcium intakes increase risk for CVD, other studies show no significant 
difference in risk in their studied population (54,55). More research is needed, especially in the 
CKD population, in order to make stronger recommendations regarding binder type and dosage. 
While it would seem there is good evidence for health practitioners to switch patients 
from calcium-based binders to non-calcium-based binders, there is another economic challenge 
that arises, which is that calcium-based binders are generally cheaper than non-calcium-based 
binders. Calcium based binders are estimated to be four to 70 times lower in yearly costs than 
non-calcium-based binders (12). Depending on the type of insurance, calcium-based binders 
might be the only option covered. In Denver, for example, patients with health insurance through 
Denver Health are only covered for calcium-based-binders with few exceptions to the rule. 
Denver Health is also the only insurance option for undocumented individuals in Denver (13). 
While obtaining accurate estimates of the number of undocumented immigrants is not easy, the 
most recent data from 2017 estimated 180,000 undocumented immigrants in the state of 
Colorado (14), with an estimated half of those individuals living in Denver Metro Area (15). 
Unless a provider is able to submit a prior authorization for a patient due to tolerance issues or 
consistent hypercalcemia, calcium-based-binders are currently the only option for these 
individuals.  
 
Velphoro  
Velphoro (sucroferric oxyhydroxide) is a phosphorus binder manufactured by Fresenius 
Medical Care. It was approved by the FDA in 2013 for use in CKD patients on dialysis (17). It 
binds the most phosphorus in the stomach, but continues to work throughout the GI tract. It does 
not interfere with fat soluble vitamins, unlike sevelamer carbonate (34,35). Each tablet contains 
500 mg iron, however the chemical makeup of the iron in Velphoro means it does not get 
absorbed into the body and therefore does not pose risk for iron overload (36). Since the binder is 
made from iron and not calcium, it subsequently has no known mechanism for increasing CVD 
risk. The tablet is meant to be broken, chewed, or crushed. It should not be taken whole. This is 
beneficial for patients who have difficulty swallowing large pills, but could be problematic for 
patients with difficulty chewing. There are other methods of taking the pill that are not approved 
by Velphoro, but are common among providers, such as dissolving the pill in a small amount of 
water, ginger ale, or other liquid.  
Velphoro has been shown to be an effective phosphorus binder, and potentially more 
effective than other binders (30). A 2018 study concluded a significant reduction in serum 
phosphorus in patients switched to Velphoro over a 16 week period (46). An early 2019 study 
showed significant reduction in serum phosphorus and PTH (p<0.05), and non significant 
reduction in serum calcium (p=0.21) (45). Two separate 2019 studies found significant reduction 
in serum phosphorus after 1 year of being switched to Velphoro (p<0.05) (44,47). Pill burden 
was also significantly reduced and serum albumin was significantly increased (p<0.05) (44). 
These studies back up the claims by Velphoro regarding significantly improved phosphorus 
control based on a 2014 study (48,49). 
Velphoro seems to positively impacts serum phosphorus, calcium, and PTH in a building 
block manner. As mentioned earlier in this paper, 1 tablet of Velphoro can bind up to 130 mg of 
phosphorus, compared to calcium acetates ability to bind approximately 106 mg of phosphorus 
(32,33). This indicates that Velphoro is a stronger binder of phosphorus, pill for pill. Because 
Velphoro is a stronger binder of phosphorus, it, in theory, requires fewer pills per day to achieve 
the same serum phosphorus control as other binders. Velphoro reports that patients on their 
medication take 52% fewer pills per day (31). I found this statistic to be true in the Rocky 
Mountain Clinic during my time as an intern. Since Velphoro has a lower pill burden that most 
other binders, patient adherence to binder regimen is better. The Canadian Agency for Drugs and 
Technologies in Health (CADTH) released a common drug review in 2018 with patient input on 
Velphoro. Some of the comments given by real patients prescribed Velphoro were very similar 
to ones I was told by patients at the Rocky Mountain clinic. Patients reported better appetite, 
enjoying meals, and less anxiety because their labs were in better control (37). 
Despite the benefits of Velphoro, the medication does have unpleasant but manageable 
side effects for some patients. Almost a quarter of patient on Velphoro experience mild diarrhea, 
16% have dark and discolored stool, and 10% experience nausea in the 6 months immediately 
following initiation of the medication (38). These side effects are not exclusive to Velphoro, and 
are reported with other phosphorus binders too. Velphoro claims no contraindications, however, 
patients with peritonitis, significant GI and hepatic disorders, those who just underwent major GI 
surgery, and those with iron overload disorders have not been researched in Velphoro clinical 
trials (39).  
As discussed earlier, Velphoro is generally a more expensive medication than other 
binders, both calcium and non-calcium based. The cost of a 90 tablet supply of Velphoro (a 1 
month supply if patient is taking 3 tablets per day, 1 with each meal) ranges from approximately 
$1,200-$1,400 (40,41). The cost of a 270 tablet supply of calcium acetate (a 1 month supply if a 
patient is taking 9 tablets per day, 3 with each meal) ranges from approximately $50-$75 (42). 
Both of these refer to the cost of the drug without insurance. Depending on the insurance, some 
or all of the cost of the drug are covered. While the patients might not take the brunt of the 
financial cost, some insurance companies require prior authorizations to approve Velphoro for a 
patient because the drug comes at a much larger cost for the insurance company compared to 
other binders (43). From my experience, patients that required a prior authorization had to prove 
that other binders were ineffective for them. This process could take weeks to months. If you’re 
just starting dialysis and don’t have insurance, you will automatically qualify for Medicare, 
however, Medicare coverage begins no earlier than the first day of the fourth month of treatment, 
leaving the first three months without guaranteed coverage of medications (56). 
 
Summary 
Phosphorus control is crucial for CKD patients on hemodialysis in regards to 
cardiovascular disease. Since the majority of dialysis patients are unable to control serum 
phosphorus through diet alone, phosphorus binders are prescribed. Increased serum phosphorus 
levels in dialysis patients disrupts bone mineral metabolism, leading to increased calcium in the 
blood that can deposit on the blood vessels and contribute CVD and death. There is currently 
concern that calcium based phosphorus binders might actually be contributing to cardiovascular 
disease due to the additional calcium being absorbed into the body from the binder, potentially 
depositing around the body and increasing risk for death from CVD (6,9,10). This has led 
KDIGO to recommend (recommendation was not given a grade) limiting the dose of calcium-
based binders in their updated 2017 guidelines (50). The relationship behind calcium based 
phosphorus binders and increased risk for CVD is not fully understood, and some studies have 
also shown no increased risk between calcium-based and non-calcium-based binders (26). 
The type of binder prescribed is the result of many factors, such as provider preference, 
patient preference, GI side effects, medical contraindications, and insurance coverage. While all 
binders have shown efficacy in controlling serum phosphorus compared to no binder, some 
binders are considered to be more effective than others. Patients switched to Velphoro from 
another phosphorus binder have shown to have statistically improved serum phosphorus control 
and reduced pill burden in multiple studies (44,45,46,47,48). It has been reasoned that serum 
calcium and PTH should also be improved on Velphoro due to improved serum phosphorus 
control, real life results have been less consistent in showing this (45).  
In the future, we need more studies looking at the relationship between calcium-based 
binders, CVD, and mortality to provide stronger evidence to be used in guidelines. Additionally, 
since Velphoro is a relatively new drug compared to other phosphorus binders, we need studies 
with longer follow ups to determine efficacy of the drug over longer times. The longest study 
cited in this paper was 1 year of follow up, yet the average life expectancy on dialysis is 5-10 
years (51).  
If a patient wants to switch to Velphoro and is financially able to do so, it has been shown 
to be a safe, very effective phosphorus binder that allows for better binder compliance and 
laboratory values due to the reduced pill burden. Above all, however, providers should take a 
patient-centered approach and talk with the patient to make sure they’re taking into account any 
financial restrictions or preferences when prescribing a phosphorus binder.  
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